Supplemental Information (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Product Information [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share |
The following table sets forth common stock equivalents that have been excluded from the computation of dilutive weighted average shares outstanding as their inclusion would have been anti-dilutive:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Receivable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Product Information [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Concentration of Credit Risk of Accounts Receivable |
Collateral is not required for accounts receivable, and we believe the carrying value approximates fair value. The following table sets forth our concentration of accounts receivable, net of specific allowances for credit losses.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||